<PAGE>
-------------------------------
/ OMB APPROVAL /
-------------------------------
/ OMB Number: 3235-0145 /
/ Expires: December 31, 1997 /
/ Estimated average burden /
/ hours per response....14.90 /
-------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 6 )*
---------
Copley Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
21745K-10-1
-----------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Page 1 of 10 Pages
<PAGE>
- -------------------------- --------------------------
CUSIP NO. 21745K-10-1 13G Page 2 of 10 Pages
------------- ----- -----
- -------------------------- --------------------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS.
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Jane C.I. Hirsh
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
1,404,563
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
1,404,563
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,404,563
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
7.32%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 10 Pages
<PAGE>
- -------------------------- --------------------------
CUSIP NO. 21745K-10-1 13G Page 3 of 10 Pages
------------- ----- -----
- -------------------------- --------------------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS.
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mark Hirsh
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
1,404,563
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
1,404,563
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,404,563
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
7.32%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 3 of 10 Pages
<PAGE>
- -------------------------- --------------------------
CUSIP NO. 21745K-10-1 13G Page 4 of 10 Pages
------------- ----- -----
- -------------------------- --------------------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS.
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Theodore L. Iorio
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 1,126,473
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
260,073
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 1,126,473
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
260,073
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,386,546
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
7.17%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 4 of 10 Pages
<PAGE>
Item 1 (a). Name of Issuer:
- ----------- ---------------
Copley Pharmaceutical, Inc.
Inc.
Item 1 (b). Address of Issuer's Principal Executive Offices:
- ----------- ------------------------------------------------
25 John Road
Canton, MA 02021
Item 2 (a). Name of Person Filing:
- ----------- ----------------------
Jane C.I. Hirsh, Mark Hirsh, Theodore L. Iorio
Item 2 (b). Address of Principal Business Office or, if none, Residence:
- ----------- ------------------------------------------------------------
The principal business address of Jane C.I. Hirsh, Mark Hirsh and
Theodore L. Iorio is Copley Pharmaceutical, Inc., 25 John Road,
Canton, MA 02021.
Item 2 (c). Citizenship:
- ----------- ------------
United States citizens
Item 2 (d). Title of Class of Securities:
- ----------- -----------------------------
Common Stock, $.01 par value per share
Item 2 (e). CUSIP Number
- ----------- ------------
21745K-10-1
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
- ------- ---------------------------------------------------------
13d-2(b), check whether the person filing is a:
-----------------------------------------------
(a) [ ] Broker or dealer registered under Section 15 of the
Act.
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a) (19)
of the Act.
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act.
(e) [ ] Investment Adviser registered under Section 203 of
the Investment Advisers Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see 13d-1 (b)
(1) (ii) (F).
Page 5 of 10 Pages
<PAGE>
(g) [ ] Parent Holding Company, in accordance with Rule
13d-1(b) (ii) (G); see Item 7.
(h) [ ] Group, in accordance with Rule 13d-1 (b) (1) (ii) (H).
Item 4. Ownership:
- ------- ----------
(a) Amount Beneficially Owned:
Jane C.I. Hirsh is the record owner of 112,500 shares (which
number includes 112,500 options exercisable within 60 days
of 12/31/98.) Ms. Hirsh may be deemed to beneficially own
25,321 shares and 7,757 shares which are allocated to
herself and her spouse, Mark Hirsh, respectively, in the
Copley Pharmaceutical, Inc. Employee Stock Ownership Plan.
By virtue of her status as the spouse of Mark Hirsh, Ms.
Hirsh may be deemed to beneficially own 170,569 shares which
Mark Hirsh owns in his capacity as the General Partner of
Romeo Partners. Ms. Hirsh may be deemed to beneficially own
888,416 shares in Copley Pharmaceutical, Inc. by virtue of
her status as the general partner of Juliet Partners. Ms.
Hirsh may be deemed to be the beneficial owner of 200,000
shares by virtue of her status as a general partner in NMJ
Limited Partnership. Therefore, Ms. Hirsh may be deemed to
beneficially own 1,404,563 shares of Common Stock. Ms. Hirsh
expressly disclaims beneficial ownership of shares of Common
Stock held of record by Mark Hirsh, Romeo Partners and/or
allocated in the Copley Pharmaceutical, Inc. Employee Stock
Ownership Plan to Mark Hirsh.
Mark Hirsh may be deemed to beneficially own 25,321 shares
and 7,757 shares which are allocated to his spouse, Jane
C.I. Hirsh, and himself, respectively, in the Copley
Pharmaceutical, Inc. Employee Stock Ownership Plan. By
virtue of his status as the spouse of Jane C.I. Hirsh, Dr.
Hirsh may be deemed to beneficially own 112,500 shares of
Common Stock which are individually owned by Jane C.I. Hirsh
(which number includes 112,500 options exercisable within 60
days of 12/31/98) and 888,416 which Jane Hirsh owns in her
capacity as the general partner of Juliet Partners. Dr.
Hirsh may be deemed to beneficially own 170,569 shares by
virtue of his status as the general partner of Romeo
Partners. Dr. Hirsh may be deemed to beneficially own
200,000 shares by virtue of his status as general partner in
NMJ Limited Partnership. Therefore, Dr. Hirsh may be deemed
to be the beneficial owner of 1,404,563 shares of Common
Stock. Dr. Hirsh expressly disclaims beneficial ownership
of shares of Common Stock held of record by Jane C.I. Hirsh,
Juliet Partners and/or allocated in the Copley
Pharmaceutical, Inc. Employee Stock Ownership Plan to Jane
C.I. Hirsh.
Theodore L. Iorio is the record owner of 286,885 shares
(which number includes 150,605 options exercisable within 60
days of 12/31/98). Additionally, Mr. Iorio may be deemed to
beneficially own: 163,932 shares which are held of record by
the Theodore L. Iorio Charitable Remainder Trust; 653,454
shares which are held of record by the Theodore L. Iorio
Standard Trust; and 22,202 shares allocated to Mr. Iorio in
the Copley Pharmaceutical, Inc. Employee Stock Ownership
Plan.
Page 6 of 10 Pages
<PAGE>
Also includes 260,073 shares held by trusts for the benefit
of certain members of Mr. Iorio's family, for which Mr.
Iorio's disclaims. Therefore Mr. Iorio may be deemed to be
the beneficial owner of 1,386,546 shares of Common Stock.
Mr. Iorio expressly disclaims beneficial ownership of shares
of Common Stock held of record by the Iorio Family
Foundation and the Theodore L. Iorio Charitable Remainder
Trust.
(b) Percent of Class:
Jane C.I. Hirsh, Mark Hirsh, and Theodore L. Iorio may be
deemed to beneficially own 7.32%, 7.32% and 7.17%
respectively (based on the 19,188,351 shares of Common Stock
reported to be outstanding on October 31, 1998 in the Copley
Pharmaceutical, Inc. Quarterly Report on Form 10-Q for the
fiscal quarter ended 9/30/98.)
(c) Number of Shares as to which such person has:
(i) sole power to vote or to direct the vote:
Jane C.I. Hirsh 0
Mark Hirsh 0
Theodore L. Iorio 1,126,473
(ii) shared power to vote or to direct the vote:
Jane C.I. Hirsh 1,404,563
Mark Hirsh 1,404,563
Theodore L. Iorio 260,073
(iii) sole power to dispose or to direct the disposition of:
Jane C.I. Hirsh 0
Mark Hirsh 0
Theodore L. Iorio 1,126,473
(iv) shared power to dispose or to direct the disposition
of:
Jane C.I. Hirsh 1,404,563
Mark Hirsh 1,404,563
Theodore L. Iorio 260,073
Item (5). Ownership of Five Percent or Less of a Class:
- --------- ---------------------------------------------
Not Applicable.
Item (6). Ownership of More than Five Percent On Behalf of Another Person:
- --------- ----------------------------------------------------------------
Not Applicable.
Item (7). Identification and Classification of the Subsidiary Which
- --------- ---------------------------------------------------------
Acquired the Security Being Reported on by the Parent Company:
--------------------------------------------------------------
Not Applicable. This statement is not filed pursuant to 13d-1(b)
(ii) (G).
Page 7 of 10 Pages
<PAGE>
Item (8). Identification and Classification of Members of the Group:
- --------- ----------------------------------------------------------
Not Applicable. This statement is not filed pursuant to 13d-1(b)
(ii) (H).
Item (9). Notice of Dissolution of Group:
- --------- -------------------------------
Not Applicable.
Item (10). Certification:
- ---------- --------------
Not Applicable. This statement is not filed pursuant to Rule
13d-1(b).
Page 8 of 10 Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: February 5, 1999
/s/ Jane C.I. Hirsh
-------------------------------
Jane C.I. Hirsh
/s/ Mark Hirsh
-------------------------------
Mark Hirsh
/s/ Theodore L. Iorio
-------------------------------
Theodore L. Iorio
Page 9 of 10 Pages
<PAGE>
EXHIBIT I
---------
Pursuant to Rule 13d-1(f)(1) under the Securities Exchange Act of
1934, the undersigned hereby agree only one statement containing the information
required on Amendment No. 6 to Schedule 13G need be filed with respect to
ownership by each of the undersigned of shares of Common Stock of Copley
Pharmaceutical, Inc.
This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original.
Dated: February 5, 1999
/s/ Jane C.I. Hirsh
-------------------------------
Jane C.I. Hirsh
/s/ Mark Hirsh
-------------------------------
Mark Hirsh
/s/ Theodore L. Iorio
-------------------------------
Theodore L. Iorio
Page 10 of 10 Pages
